Cargando…
Patient Understanding of the Neuropsychiatric Risks Associated with Branded Bupropion Hydrochloride Products Used for Smoking Cessation
BACKGROUND: Bupropion hydrochloride (Zyban) is an effective aid to smoking cessation; however, its use has previously been associated with neuropsychiatric adverse events. Here we report results of the patient Knowledge, Attitudes, and Behavior survey that forms part of the Year 7 Risk Evaluation an...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6119167/ https://www.ncbi.nlm.nih.gov/pubmed/30105744 http://dx.doi.org/10.1007/s40801-018-0140-2 |
_version_ | 1783352034490056704 |
---|---|
author | Ascher, John Stemhagen, Annette Stender, Monika Win, Beta Winter, Christina |
author_facet | Ascher, John Stemhagen, Annette Stender, Monika Win, Beta Winter, Christina |
author_sort | Ascher, John |
collection | PubMed |
description | BACKGROUND: Bupropion hydrochloride (Zyban) is an effective aid to smoking cessation; however, its use has previously been associated with neuropsychiatric adverse events. Here we report results of the patient Knowledge, Attitudes, and Behavior survey that forms part of the Year 7 Risk Evaluation and Mitigation Strategy (REMS) assessment for Zyban. OBJECTIVE: Assess participants’ understanding of the neuropsychiatric risks associated with branded bupropion hydrochloride products that are used for smoking cessation, as described in the Medication Guides. METHODS: A cross-sectional study was conducted among patients ≥ 18 years of age, who had used or filled a prescription for branded bupropion hydrochloride for smoking cessation in the past 6 months. Participants were recruited through an online panel, pharmacy network, or by healthcare provider referral, and invited to complete a survey containing questions regarding the risks associated with the use of branded bupropion hydrochloride products, and whether they had received and read the Medication Guide. The study aimed for ≥ 80% of participants to respond correctly to each question regarding neuropsychiatric risks. RESULTS: From the 50,985 survey invitations distributed, 1017 participants responded, of whom 144 were eligible and 142 completed the survey. Over 80% of participants correctly responded to most neuropsychiatric risk questions. Approximately three-quarters of participants received the Medication Guide when they last filled their prescription, of whom over half read the Medication Guide at that time. CONCLUSIONS: Participants enrolled in this Year 7 REMS survey had good understanding of the neuropsychiatric risks associated with using branded bupropion hydrochloride products for smoking cessation. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s40801-018-0140-2) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-6119167 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Springer International Publishing |
record_format | MEDLINE/PubMed |
spelling | pubmed-61191672018-09-10 Patient Understanding of the Neuropsychiatric Risks Associated with Branded Bupropion Hydrochloride Products Used for Smoking Cessation Ascher, John Stemhagen, Annette Stender, Monika Win, Beta Winter, Christina Drugs Real World Outcomes Original Research Article BACKGROUND: Bupropion hydrochloride (Zyban) is an effective aid to smoking cessation; however, its use has previously been associated with neuropsychiatric adverse events. Here we report results of the patient Knowledge, Attitudes, and Behavior survey that forms part of the Year 7 Risk Evaluation and Mitigation Strategy (REMS) assessment for Zyban. OBJECTIVE: Assess participants’ understanding of the neuropsychiatric risks associated with branded bupropion hydrochloride products that are used for smoking cessation, as described in the Medication Guides. METHODS: A cross-sectional study was conducted among patients ≥ 18 years of age, who had used or filled a prescription for branded bupropion hydrochloride for smoking cessation in the past 6 months. Participants were recruited through an online panel, pharmacy network, or by healthcare provider referral, and invited to complete a survey containing questions regarding the risks associated with the use of branded bupropion hydrochloride products, and whether they had received and read the Medication Guide. The study aimed for ≥ 80% of participants to respond correctly to each question regarding neuropsychiatric risks. RESULTS: From the 50,985 survey invitations distributed, 1017 participants responded, of whom 144 were eligible and 142 completed the survey. Over 80% of participants correctly responded to most neuropsychiatric risk questions. Approximately three-quarters of participants received the Medication Guide when they last filled their prescription, of whom over half read the Medication Guide at that time. CONCLUSIONS: Participants enrolled in this Year 7 REMS survey had good understanding of the neuropsychiatric risks associated with using branded bupropion hydrochloride products for smoking cessation. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s40801-018-0140-2) contains supplementary material, which is available to authorized users. Springer International Publishing 2018-08-13 /pmc/articles/PMC6119167/ /pubmed/30105744 http://dx.doi.org/10.1007/s40801-018-0140-2 Text en © The Author(s) 2018 Open AccessThis article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. |
spellingShingle | Original Research Article Ascher, John Stemhagen, Annette Stender, Monika Win, Beta Winter, Christina Patient Understanding of the Neuropsychiatric Risks Associated with Branded Bupropion Hydrochloride Products Used for Smoking Cessation |
title | Patient Understanding of the Neuropsychiatric Risks Associated with Branded Bupropion Hydrochloride Products Used for Smoking Cessation |
title_full | Patient Understanding of the Neuropsychiatric Risks Associated with Branded Bupropion Hydrochloride Products Used for Smoking Cessation |
title_fullStr | Patient Understanding of the Neuropsychiatric Risks Associated with Branded Bupropion Hydrochloride Products Used for Smoking Cessation |
title_full_unstemmed | Patient Understanding of the Neuropsychiatric Risks Associated with Branded Bupropion Hydrochloride Products Used for Smoking Cessation |
title_short | Patient Understanding of the Neuropsychiatric Risks Associated with Branded Bupropion Hydrochloride Products Used for Smoking Cessation |
title_sort | patient understanding of the neuropsychiatric risks associated with branded bupropion hydrochloride products used for smoking cessation |
topic | Original Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6119167/ https://www.ncbi.nlm.nih.gov/pubmed/30105744 http://dx.doi.org/10.1007/s40801-018-0140-2 |
work_keys_str_mv | AT ascherjohn patientunderstandingoftheneuropsychiatricrisksassociatedwithbrandedbupropionhydrochlorideproductsusedforsmokingcessation AT stemhagenannette patientunderstandingoftheneuropsychiatricrisksassociatedwithbrandedbupropionhydrochlorideproductsusedforsmokingcessation AT stendermonika patientunderstandingoftheneuropsychiatricrisksassociatedwithbrandedbupropionhydrochlorideproductsusedforsmokingcessation AT winbeta patientunderstandingoftheneuropsychiatricrisksassociatedwithbrandedbupropionhydrochlorideproductsusedforsmokingcessation AT winterchristina patientunderstandingoftheneuropsychiatricrisksassociatedwithbrandedbupropionhydrochlorideproductsusedforsmokingcessation |